Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.50
MRK's Cash to Debt is ranked lower than
74% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. MRK: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.5
0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked lower than
75% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.44
0.34
0.53
Interest Coverage 10.67
MRK's Interest Coverage is ranked lower than
63% of the 468 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.86 vs. MRK: 10.67 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 3.31  Med: 9.85 Max: 20.11
Current: 10.67
3.31
20.11
F-Score: 7
Z-Score: 3.08
M-Score: -2.75
WACC vs ROIC
6.66%
10.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.42
MRK's Operating margin (%) is ranked higher than
79% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. MRK: 18.42 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 5.15  Med: 15.81 Max: 21.86
Current: 18.42
5.15
21.86
Net-margin (%) 11.72
MRK's Net-margin (%) is ranked higher than
70% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. MRK: 11.72 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.30 Max: 47.04
Current: 11.72
1.87
47.04
ROE (%) 10.11
MRK's ROE (%) is ranked higher than
61% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. MRK: 10.11 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.52  Med: 14.91 Max: 42.27
Current: 10.11
1.52
42.27
ROA (%) 4.50
MRK's ROA (%) is ranked higher than
54% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. MRK: 4.50 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.50 Max: 16.34
Current: 4.5
0.79
16.34
ROC (Joel Greenblatt) (%) 46.34
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. MRK: 46.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 45.71 Max: 105.49
Current: 46.34
10.88
105.49
Revenue Growth (3Y)(%) -3.30
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -24  Med: 3.60 Max: 23.1
Current: -3.3
-24
23.1
EBITDA Growth (3Y)(%) -6.40
MRK's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.7  Med: 6.10 Max: 25.8
Current: -6.4
-15.7
25.8
EPS Growth (3Y)(%) -7.90
MRK's EPS Growth (3Y)(%) is ranked lower than
70% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: 0.20 Max: 74.6
Current: -7.9
-43
74.6
» MRK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MRK Guru Trades in Q2 2015

David Dreman 11,463 sh (New)
Ray Dalio 17,141 sh (New)
Kyle Bass 35,404 sh (New)
Manning & Napier Advisors, Inc 6,347,239 sh (+1493.37%)
Jim Simons 1,921,734 sh (+60.93%)
PRIMECAP Management 2,042,000 sh (+47.44%)
Charles Brandes 2,817,473 sh (+26.81%)
Pioneer Investments 3,279,231 sh (+19.08%)
Vanguard Health Care Fund 45,748,498 sh (+14.09%)
Barrow, Hanley, Mewhinney & Strauss 25,641,122 sh (+4.81%)
Ken Fisher 6,836,547 sh (+2.35%)
Murray Stahl 41,151 sh (+0.24%)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Richard Snow 5,375 sh (unchged)
Tom Russo 3,836 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
T Rowe Price Equity Income Fund 6,625,700 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 145,134 sh (-0.14%)
Kahn Brothers 1,016,613 sh (-1.28%)
Mairs and Power 102,874 sh (-2.17%)
Dodge & Cox 24,680,781 sh (-3.02%)
NWQ Managers 73,790 sh (-3.27%)
Mario Gabelli 148,540 sh (-7.71%)
RS Investment Management 747,565 sh (-16.78%)
Jeremy Grantham 6,500 sh (-27.15%)
Paul Tudor Jones 16,900 sh (-82.59%)
» More
Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
David Carlson 250,000 sh (unchged)
Prem Watsa 12,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Kyle Bass Sold Out
RS Investment Management Sold Out
David Dreman Sold Out
Tom Russo Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
Barrow, Hanley, Mewhinney & Strauss 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

John Buckingham 24,665 sh (New)
Tom Russo 3,836 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Jeremy Grantham 4,200 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

David Dreman 710 sh (New)
Richard Pzena 921,365 sh (New)
John Burbank 1,370,117 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
Tom Russo 3,836 sh (unchged)
David Carlson 250,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:NVS, NYSE:BMY, NYSE:PFE, OTCPK:GLAXF, NYSE:SNY, NYSE:ABBV, NYSE:LLY, OTCPK:BAYRY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:OPHLY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, NAS:ZSPH, NAS:GWPH » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company's operations are managed on a products basis and are comprised of four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The Pharmaceutical segment is the only reportable segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, administered at physician offices. The Company sells these human health vaccines to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The Alliances segment includes results from the Company's relationship with AstraZeneca LP until the termination of that relationship on June 30, 2014. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Products within the Company's franchises are - Primary Care and Women's Health include Cardiovascular, Diabetes, and General Medicine and Women's Health; Hospital and Specialty include Hepatitis, HIV, Hospital Acute Care, and Immunology; Oncology includes Keytruda, Emend, Temodar, and Temodal; Diversified Brands includes Respiratory and Others; and Vaccines. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. Principal products in this segment include - Livestock Products; Poultry Products; Companion Animal Products; and Aquaculture Products. The Company's competitors include other research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers and animal health care companies.

Ratios

vs
industry
vs
history
P/E(ttm) 34.09
MRK's P/E(ttm) is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.34 vs. MRK: 34.09 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.67  Med: 19.03 Max: 139.89
Current: 34.09
6.67
139.89
Forward P/E 15.02
MRK's Forward P/E is ranked higher than
52% of the 65 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. MRK: 15.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.09
MRK's PE(NRI) is ranked lower than
61% of the 533 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.24 vs. MRK: 34.09 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.65  Med: 19.00 Max: 133.39
Current: 34.09
6.65
133.39
Price/Owner Earnings (ttm) 18.87
MRK's Price/Owner Earnings (ttm) is ranked higher than
74% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.00 vs. MRK: 18.87 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.1  Med: 15.60 Max: 48.31
Current: 18.87
6.1
48.31
P/B 3.51
MRK's P/B is ranked lower than
62% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. MRK: 3.51 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.21 Max: 7.25
Current: 3.51
1.72
7.25
P/S 3.96
MRK's P/S is ranked lower than
63% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. MRK: 3.96 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.25 Max: 5.48
Current: 3.96
2.02
5.48
PFCF 14.41
MRK's PFCF is ranked higher than
76% of the 189 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.95 vs. MRK: 14.41 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 15.79 Max: 89.14
Current: 14.41
7.87
89.14
POCF 12.83
MRK's POCF is ranked higher than
65% of the 254 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.49 vs. MRK: 12.83 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 13.02 Max: 35.89
Current: 12.83
6.67
35.89
EV-to-EBIT 26.36
MRK's EV-to-EBIT is ranked lower than
64% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.96 vs. MRK: 26.36 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.30 Max: 52.6
Current: 26.36
4.9
52.6
EV-to-EBITDA 13.22
MRK's EV-to-EBITDA is ranked higher than
62% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.28 vs. MRK: 13.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.50 Max: 20.4
Current: 13.22
4.2
20.4
PEG 3.73
MRK's PEG is ranked lower than
70% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. MRK: 3.73 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.55  Med: 2.64 Max: 28.4
Current: 3.73
0.55
28.4
Shiller P/E 21.75
MRK's Shiller P/E is ranked higher than
78% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.12 vs. MRK: 21.75 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 7.55  Med: 15.22 Max: 24.67
Current: 21.75
7.55
24.67
Current Ratio 1.64
MRK's Current Ratio is ranked lower than
68% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 1.64 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.64
1.07
3.7
Quick Ratio 1.35
MRK's Quick Ratio is ranked lower than
63% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. MRK: 1.35 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.26 Max: 3.44
Current: 1.35
0.8
3.44
Days Inventory 125.94
MRK's Days Inventory is ranked lower than
57% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. MRK: 125.94 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.17
Current: 125.94
104.23
205.17
Days Sales Outstanding 63.48
MRK's Days Sales Outstanding is ranked higher than
59% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. MRK: 63.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 58.77 Max: 87.87
Current: 63.48
44.5
87.87
Days Payable 54.76
MRK's Days Payable is ranked lower than
64% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. MRK: 54.76 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.82
Current: 54.76
30.2
90.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.29
MRK's Dividend Yield is ranked higher than
79% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. MRK: 3.29 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.85 Max: 6.68
Current: 3.29
2.51
6.68
Dividend Payout 1.11
MRK's Dividend Payout is ranked lower than
72% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. MRK: 1.11 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 3.8
Current: 1.11
0.16
3.8
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
62% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.80 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 3.31
MRK's Forward Dividend Yield is ranked higher than
77% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. MRK: 3.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.93
MRK's Yield on cost (5-Year) is ranked higher than
75% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. MRK: 3.93 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.62 Max: 8.01
Current: 3.93
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 424 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.10 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.08
MRK's Price/Tangible Book is ranked lower than
98% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. MRK: 33.08 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 33.08
3.19
3112.5
Price/Projected FCF 1.26
MRK's Price/Projected FCF is ranked higher than
76% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. MRK: 1.26 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.26
0.75
3.04
Price/Median PS Value 1.23
MRK's Price/Median PS Value is ranked lower than
61% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. MRK: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.22 Max: 2.02
Current: 1.23
0.66
2.02
Price/Peter Lynch Fair Value 3.85
MRK's Price/Peter Lynch Fair Value is ranked lower than
88% of the 172 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. MRK: 3.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.64 Max: 10.1
Current: 3.85
0.58
10.1
Price/Graham Number 7.08
MRK's Price/Graham Number is ranked lower than
91% of the 409 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. MRK: 7.08 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.08  Med: 3.64 Max: 32.76
Current: 7.08
1.08
32.76
Earnings Yield (Greenblatt) (%) 3.82
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 3.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 7.00 Max: 20.6
Current: 3.82
1.9
20.6
Forward Rate of Return (Yacktman) (%) 14.27
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.89 vs. MRK: 14.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.60 Max: 22.2
Current: 14.27
-5.7
22.2

More Statistics

Revenue (TTM) (Mil) $39,385
EPS (TTM) $ 1.63
Beta0.75
Short Percentage of Float1.12%
52-Week Range $45.69 - 60.07
Shares Outstanding (Mil)2,768.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 39,248 38,823 40,164
EPS ($) 3.71 3.76 3.91
EPS w/o NRI ($) 3.71 3.76 3.91
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
» More Articles for NYSE:MRK

Headlines

Articles On GuruFocus.com
Market Indexes Higher With Volatility Lower May 25 2016 
The PBM Empire Strikes Back May 10 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Market Indexes Flat as Economic Indicators Still Point Lower May 08 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Merck CEO Kenneth Frazier Sells 131,040 Shares Apr 15 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
An Attempt to Value Valeant Just for Fun Mar 23 2016 
Whole Foods' Green Initiatives Will Pay Off for Investors Mar 22 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 

More From Other Websites
7:01 am Merck announces strategic collaboration and license agreement with Moderna Therapeutics,... Jun 29 2016
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer... Jun 29 2016
Merck Receives Frost & Sullivan Award for Meoxal® and Xirallic® NXT Lines Jun 29 2016
FDA approves first pill to treat all forms of hepatitis C Jun 28 2016
FDA approves first pill to treat all forms of hepatitis C Jun 28 2016
Gilead Sciences: Dominating Jun 28 2016
Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : June 28, 2016 Jun 28 2016
Merck Expands Industry-Leading Emprove® Program to Include Filtration and Single-Use Products Jun 28 2016
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute Jun 28 2016
The Largest Drug Pipelines Will Surprise You Jun 27 2016
Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment Jun 27 2016
Short Sellers Increase Bets Against Major Pharmaceutical Stocks Jun 27 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced... Jun 27 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced... Jun 27 2016
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Jun 24 2016
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Jun 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)